Silence Therapeutics PLC Additional Listing (3542C)
April 12 2017 - 7:30AM
UK Regulatory
TIDMSLN
RNS Number : 3542C
Silence Therapeutics PLC
12 April 2017
Additional listing
12 April 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that it has issued and allotted 190,000 new
ordinary shares of 5p each ("Ordinary Shares") following the
exercise of share options under the Employee Share Scheme.
Application has been made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM. Admission is
expected to be effective on 20 April 2017. The Ordinary Shares
shall rank pari passu with the existing ordinary shares in the
Company.
The total number of shares in issue, following admission, will
be 69,991,624. The Company holds no shares in Treasury.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Canaccord Genuity Limited (Nominated Tel: +44 (0)20
Adviser and Joint Broker) 7523 8350
Henry Fitzgerald-O'Connor/Emma
Gabriel
Peel Hunt LLP (Joint Broker) Tel: +44 (0)20
James Steel/Oliver Jackson 7418 8900
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSGGURPCUPMGPP
(END) Dow Jones Newswires
April 12, 2017 08:30 ET (12:30 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Silence Therapeutics Plc (London Stock Exchange): 0 recent articles
More Silence Ther. News Articles